Unnamed: 0,title,date,stock,sentiment
817240.0,"The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test",2020-05-20 08:12:00-04:00,MDWD,neutral
817241.0,MediWound shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.,2020-05-20 07:22:00-04:00,MDWD,positive
817242.0,30 Stocks Moving in Wednesday's Pre-Market Session,2020-05-20 07:16:00-04:00,MDWD,neutral
817243.0,Recap: MediWound Q1 Earnings,2020-05-20 07:13:00-04:00,MDWD,neutral
817244.0,"MediWound Q1 EPS $(0.090) Beats $(0.140) Estimate, Sales $4.400M Beat $4.050M Estimate",2020-05-20 07:01:00-04:00,MDWD,neutral
817245.0,"The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Earnings Flow Slows",2020-05-17 12:30:00-04:00,MDWD,positive
817246.0,MediWound Announces Distributin Agreements For NexoBrid,2020-05-04 07:34:00-04:00,MDWD,positive
817247.0,"The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO",2020-04-03 07:36:00-04:00,MDWD,neutral
817248.0,108 Biggest Movers From Yesterday,2020-03-11 05:34:00-04:00,MDWD,neutral
817249.0,82 Stocks Moving In Tuesday's Mid-Day Session,2020-03-10 12:25:00-04:00,MDWD,neutral
817250.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,MDWD,negative
817251.0,140 Biggest Movers From Friday,2020-03-02 04:43:00-05:00,MDWD,neutral
817252.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,MDWD,neutral
817253.0,Stocks That Hit 52-Week Lows On Thursday,2020-02-27 10:23:00-05:00,MDWD,negative
817254.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,MDWD,positive
817255.0,"MediWound Q4 EPS $(0.13) Misses $(0.1) Estimate, Sales $5.442M Beat $4.08M Estimate",2020-02-25 07:22:00-05:00,MDWD,negative
817256.0,MediWound Expands its Distribution Agreement with GENFA MEDICA SA to Market NexoBrid in Ukraine and the Baltic States,2020-01-13 08:27:00-05:00,MDWD,positive
817257.0,MediWound and Vericel's NexoBrid Receives $16.5M of Orders from the US Biomedical Advanced Research and Development Authority for Emergency Stockpiling,2020-01-06 06:36:00-05:00,MDWD,negative
817258.0,"MediWound Announces New Distribution Agreement In Australia, New Zealand And Singapore With Balance Medical",2020-01-02 07:33:00-05:00,MDWD,positive
817259.0,MediWound Initiates US Phase 2 Adaptive Design Study of EscharEx for Treatment of Venous Leg Ulcers,2019-12-03 07:34:00-05:00,MDWD,neutral
817260.0,"MediWound Q3 EPS $(0.11) Beats $(0.15) Estimate, Sales $5.14M Beat $2.08M Estimate",2019-11-14 07:14:00-05:00,MDWD,neutral
817261.0,Vericel Analyst Projects Wound Care Product Sales Will Grow Fivefold By 2025,2019-10-09 15:09:00-04:00,MDWD,positive
817262.0,Vericel And MediWound Announce Initiation Of US NexoBrid Expanded Access Treatment Protocol,2019-10-02 07:30:00-04:00,MDWD,neutral
817263.0,MediWound Says Entered Into Series Of Settlement Agreements With PolyHeal; Co. Paid ~$2.8M And Received 14.473K Shares Of PolyHeal,2019-10-02 07:21:00-04:00,MDWD,positive
817264.0,"MediWound Q2 EPS $(0.12) Misses $(0.03) Estimate, Sales $20.7M Do Not Compare to $4.45M Estimate",2019-08-12 14:59:00-04:00,MDWD,negative
817265.0,70 Biggest Movers From Yesterday,2019-08-06 04:46:00-04:00,MDWD,neutral
817266.0,New 52-Week Lows For Monday Morning,2019-08-05 13:16:00-04:00,MDWD,negative
817267.0,"Benzinga's Top Upgrades, Downgrades For August 5, 2019",2019-08-05 10:29:00-04:00,MDWD,positive
817268.0,"H.C. Wainwright Initiates Coverage On MediWound with Buy Rating, Announces $5.5 Price Target",2019-08-05 07:31:00-04:00,MDWD,neutral
817269.0,Stocks That Set New 52-Week Lows Friday Morning,2019-08-02 10:46:00-04:00,MDWD,negative
817270.0,Stocks that Reached Yearly Lows Thursday Morning,2019-08-01 11:09:00-04:00,MDWD,negative
817271.0,"The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings",2019-08-01 07:18:00-04:00,MDWD,negative
817272.0,New 52-Week Low Achievers For Wednesday Morning,2019-07-31 11:16:00-04:00,MDWD,negative
817273.0,42 Stocks Moving In Wednesday's Pre-Market Session,2019-07-31 08:17:00-04:00,MDWD,neutral
817274.0,64 Biggest Movers From Yesterday,2019-07-26 04:36:00-04:00,MDWD,neutral
817275.0,50 Biggest Movers From Yesterday,2019-07-25 05:50:00-04:00,MDWD,neutral
817276.0,MediWound Launches EscharEx US Clinical Development Program,2019-07-22 07:02:00-04:00,MDWD,neutral
817277.0,55 Biggest Movers From Friday,2019-07-22 04:44:00-04:00,MDWD,neutral
817278.0,41 Stocks Moving In Friday's Mid-Day Session,2019-07-19 12:21:00-04:00,MDWD,neutral
817279.0,60 Biggest Movers From Yesterday,2019-06-25 05:12:00-04:00,MDWD,neutral
817280.0,40 Stocks Moving In Monday's Mid-Day Session,2019-06-24 12:35:00-04:00,MDWD,neutral
817281.0,68 Biggest Movers From Friday,2019-06-24 04:25:00-04:00,MDWD,neutral
817282.0,"The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut",2019-06-19 07:51:00-04:00,MDWD,positive
817283.0,MediWound Appoints Mr. Boaz Gur-Lavie As CFO,2019-06-11 07:34:00-04:00,MDWD,neutral
817284.0,MediWound Receives Marketing Authorization For NexoBrid From Peru's Ministry Of Health,2019-06-04 07:32:00-04:00,MDWD,neutral
817285.0,"MediWound Q1 EPS $(0.15) Misses $(0.13) Estimate, Sales $461K Miss $560K Estimate",2019-05-21 07:08:00-04:00,MDWD,negative
817286.0,72 Biggest Movers From Yesterday,2019-05-08 06:17:00-04:00,MDWD,neutral
817287.0,"MediWound Enters into Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid in N. America; MediWound to Receive Upfront Payment of $17.5M, $7.5M on U.S. BLA Approval, Up to $125M in Sales Milestones",2019-05-07 04:26:00-04:00,MDWD,positive
817288.0,"MediWound Announces a $125M Share, Warrant, Debt Offering and 11.24M Share Offering by Selling Shareholders",2019-03-25 16:21:00-04:00,MDWD,positive
817289.0,"MediWound Q4 EPS $0.22 May Not Compare to $(0.15) Estimate, Sales $992K Beat $810K Estimate",2019-03-25 07:07:00-04:00,MDWD,neutral
817290.0,"Earnings Scheduled For March 25, 2019",2019-03-25 04:59:00-04:00,MDWD,neutral
817291.0,"MediWound Shares Resume Trade Following Circuit Breaker, Now Up 15%",2019-03-12 10:37:00-04:00,MDWD,positive
817292.0,"Mediwound Shares Halted On Circuit Breaker, Now Up 12.5%",2019-03-12 10:32:00-04:00,MDWD,positive
817293.0,"Mediwound Shares Spike To Session High, Up 3.7%, As Traders Circulate Comment From SunTrust Analysts They Believe The Co. Is Close To Being Acquired",2019-03-12 10:32:00-04:00,MDWD,positive
817294.0,35 Stocks Moving In Friday's Pre-Market Session,2019-02-01 08:33:00-05:00,MDWD,neutral
817295.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Wed., Jan. 23, 2019",2019-01-23 09:41:00-05:00,MDWD,positive
817296.0,55 Biggest Movers From Yesterday,2019-01-23 05:19:00-05:00,MDWD,neutral
817297.0,50 Stocks Moving In Tuesday's Mid-Day Session,2019-01-22 12:21:00-05:00,MDWD,neutral
817298.0,Mid-Day Market Update: Crude Oil Down Over 3%; Staffing 360 Solutions Shares Jump,2019-01-22 12:02:00-05:00,MDWD,negative
817299.0,Mid-Morning Market Update: Markets Open Lower; Johnson & Johnson Profit Tops Expectations,2019-01-22 10:17:00-05:00,MDWD,positive
817300.0,24 Stocks Moving In Tuesday's Pre-Market Session,2019-01-22 08:04:00-05:00,MDWD,neutral
817301.0,A Peek Into The Markets: US Stock Futures Drop Ahead Of Earnings,2019-01-22 06:44:00-05:00,MDWD,negative
817302.0,MediWound Reports Phase 3 Study Of NexoBrid Met Primary And All Secondary Endpoints With Statistically Significant Results Compared With Control Group,2019-01-22 06:33:00-05:00,MDWD,positive
817303.0,"MediWound Q3 EPS $(0.11) Up From $(0.16) YoY, Sales $900K Miss $1.11M Estimate",2018-11-13 07:03:00-05:00,MDWD,negative
817304.0,"MediWound Announces a Contract With $12M of Funding to Support R&D, Options for Up to $31M of Additional Funding",2018-09-24 07:13:00-04:00,MDWD,positive
817305.0,"A Peek Into The Markets: US Stock Futures Down Ahead Of Economic Data, Fed Speakers",2018-09-05 07:20:00-04:00,MDWD,neutral
817306.0,"MediWound Announces That Its NexoBrid Received Marketing Authorization Form Russia's Ministry Of Health, Commercial Launch Is Expected In The First Half Of 2019",2018-09-05 07:02:00-04:00,MDWD,neutral
817307.0,"MediWound Q2 EPS $(0.32) Misses $(0.20) Estimate, Sales $1.551M Beat $980K Estimate",2018-08-07 07:02:00-04:00,MDWD,negative
817308.0,MediWound Reports Expansion Of NexoBrid Phase 3 Children Innovation Debridement Study To US Burn Centers,2018-06-19 07:09:00-04:00,MDWD,positive
817309.0,MediWound Completes Enrollment In U.S. Phase 3 DETECT Study For NexoBrid Topical Burn Treatment; Topline Data Expected Around Year End 2018,2018-06-11 07:09:00-04:00,MDWD,neutral
817310.0,NexoBrid Receives Marketing Authorization From South Korea's Ministry of Health,2018-06-04 07:06:00-04:00,MDWD,neutral
817311.0,MediWound Announces FDA Clears Development Pathway for NexoBrid,2018-05-29 08:03:00-04:00,MDWD,positive
817312.0,"MediWound Q1 EPS $(0.17) Misses $(0.16) Estimate, Sales $520K Miss $580K Estimate",2018-05-10 09:12:00-04:00,MDWD,negative
817313.0,33 Biggest Movers From Yesterday,2018-03-21 05:30:00-04:00,MDWD,neutral
817314.0,28 Stocks Moving In Tuesday's Mid-Day Session,2018-03-20 13:46:00-04:00,MDWD,neutral
817315.0,42 Biggest Movers From Yesterday,2018-03-20 04:48:00-04:00,MDWD,neutral
817316.0,31 Stocks Moving In Monday's Mid-Day Session,2018-03-19 12:49:00-04:00,MDWD,neutral
817317.0,"MediWound Reports Q4 EPS $(0.09) Beats $(0.17) Est., Sales $530K Misses $630K Est.",2018-03-19 07:05:00-04:00,MDWD,negative
817318.0,"Earnings Scheduled For March 19, 2018",2018-03-19 04:04:00-04:00,MDWD,neutral
817319.0,"MediWound Reports Q3 EPS $(0.90) vs $(0.78) In Prior Year Period, Sales $1.96M vs $790K Est.",2017-11-16 07:08:00-05:00,MDWD,neutral
817320.0,MediWound Names Stephen Wills Chair,2017-10-25 07:29:00-04:00,MDWD,neutral
817321.0,"Benzinga's Top Upgrades, Downgrades For September 28, 2017",2017-09-28 09:08:00-04:00,MDWD,positive
817322.0,"Cowen & Co. Initiates Coverage On MediWound Ltd. - Ordinary Shares with Outperform Rating, Announces $9.00 Price Target",2017-09-28 07:55:00-04:00,MDWD,positive
817323.0,Mid-Afternoon Market Update: Crude Oil Down Over 1%; Synchronoss Technologies Shares Slide,2017-09-19 14:38:00-04:00,MDWD,negative
817324.0,15 Biggest Mid-Day Losers For Tuesday,2017-09-19 12:45:00-04:00,MDWD,negative
817325.0,Mid-Day Market Update: Bob Evans Farms Rises On Acquisition News; Mediwound Shares Plunge,2017-09-19 12:06:00-04:00,MDWD,positive
817326.0,Mid-Morning Market Update: Markets Edge Higher; AutoZone Earnings Top Expectations,2017-09-19 10:08:00-04:00,MDWD,positive
817327.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-09-19 08:10:00-04:00,MDWD,neutral
817328.0,A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Fed Meeting,2017-09-19 07:48:00-04:00,MDWD,neutral
817329.0,MediWound Prices $22M Offering at $5/Share,2017-09-19 06:32:00-04:00,MDWD,neutral
817330.0,"MediWound Announces Shelf Offering Common Stock, No Size Disclosed",2017-09-18 16:08:00-04:00,MDWD,negative
817331.0,"MediWound Successfully Completes Second Cohort of EscharEx Phase 2 Study, Says No Related Systemic Adverse Events Were Reported And That Adverse Events Related TO Local Application Were Mild To Moderate, Reversible and Resolved",2017-09-01 08:02:00-04:00,MDWD,negative
817332.0,"MediWound Reports Q2 EPS $(0.40) vs $(0.20) Est., Sales $1.227M vs $740K Est.",2017-08-03 08:24:00-04:00,MDWD,neutral
817333.0,MediWound Reports Upsizing Of BARDA Contract Commitment Funds From $24M To ~$56M,2017-07-19 16:54:00-04:00,MDWD,positive
817334.0,"MediWound Q1 EPS $(0.20) vs $(0.17) Est, Sales $540K vs $630K Est",2017-05-08 07:09:00-04:00,MDWD,neutral
817335.0,"MediWound Q4 EPS $(0.09) vs $(0.25) Est, Revenue $430K vs $730K Est",2017-02-21 07:04:00-05:00,MDWD,neutral
817336.0,MediWound Says Results from NexoBrid Phase 2 Pharmacokinetic Clinical Study Support Treatment of Severe Burns Covering up to 30% of Total Body Surface Area,2017-02-09 07:27:00-05:00,MDWD,neutral
817337.0,MediWound Begins Second Stage of European Pediatric Phase 3 Study of NexoBrid,2017-02-06 07:01:00-05:00,MDWD,neutral
817338.0,"MediWound Reports Final Positive Results of Phase 2 Clinical Trial of EscharEx, Data Reported Supports Positive Top-Line Results And No Significant Safety Concerns Observed",2017-01-31 07:04:00-05:00,MDWD,positive
817339.0,MediWound Granted Patent for MWPC003 for the Treatment of Connective Tissue Diseases,2016-12-20 07:06:00-05:00,MDWD,positive
817340.0,Benzinga's Top Initiations,2016-11-28 09:19:00-05:00,MDWD,positive
817341.0,"Aegis Capital Initiates Coverage On MediWound Ltd. - Ordinary Shares at Buy, Announces $11.00 Target",2016-11-28 07:25:00-05:00,MDWD,positive
817342.0,"MediWound Q3 EPS $(0.26) vs $(0.78) Est, Revenue $1.13M vs 0.58M Est",2016-11-14 06:47:00-05:00,MDWD,neutral
817343.0,18 Biggest Mid-Day Gainers For Wednesday,2016-08-17 12:54:00-04:00,MDWD,neutral
817344.0,Benzinga's Top Initiations,2016-08-17 09:30:00-04:00,MDWD,positive
817345.0,Wells Fargo Initiates Coverage on MediWound at Outperform,2016-08-17 07:32:00-04:00,MDWD,positive
817346.0,"MediWound Reports Q2 EPS $(0.34) vs. Est $(0.23), Rev. $356K vs. Est. $450K",2016-07-28 09:15:00-04:00,MDWD,neutral
817347.0,MediWound Reports NexoBrid Received Reimbursement in Italy,2016-06-07 07:06:00-04:00,MDWD,neutral
817348.0,"MediWound Reports Q1 EPS $(0.17) vs. Est. $(0.24), Rev. $254K vs. Est. $280K",2016-04-21 07:01:00-04:00,MDWD,neutral
817349.0,Mediwound Reports Top-Line Results from Phase 2 Study with EscharEx to Treat Chronic Wounds Will Be Presented at Symposium on Advanced Wound Care,2016-04-08 07:02:00-04:00,MDWD,positive
817350.0,"SunTrust Robinson Humphrey Initiates Coverage on MediWound at Buy, Announces $13.00 PT",2016-03-23 08:27:00-04:00,MDWD,neutral
817351.0,MediWound Meets Primary Endpoint For Phase 2 Trial For Debridement Of Chronic Hard-To-Heal Wounds,2016-02-02 16:58:00-05:00,MDWD,neutral
817352.0,Earnings Recap For January 25,2016-01-25 16:41:00-05:00,MDWD,neutral
817353.0,"F-3 from MediWound Shows Registration for $125M in Common Shares, Warrants and Debt, Up to ~11.64M Common Shares by Selling Holders",2016-01-25 16:39:00-05:00,MDWD,positive
817354.0,"Mediwount Q4 EPS -$0.36 vs -$0.23 est, Revenue $267K vs $230K est",2016-01-25 07:01:00-05:00,MDWD,neutral
817355.0,"Earnings Scheduled For January 25, 2016",2016-01-25 04:00:00-05:00,MDWD,neutral
817356.0,MediWound Reports Expansion of LatAm Distribution Deal with Avalon Pharma for NexoBrid,2016-01-21 08:03:00-05:00,MDWD,neutral
817357.0,Benzinga's Top Initiations,2016-01-11 10:04:00-05:00,MDWD,positive
817358.0,"Brean Capital Initiates Coverage on MediWound at Buy, Announces $20.00 PT",2016-01-11 07:29:00-05:00,MDWD,neutral
817359.0,"Brean Capital Initiates Coverage on MediWound at Buy, Announces $20.00 PT",2016-01-08 14:35:00-05:00,MDWD,neutral
817360.0,MediWound Names Aharon Yaari as Chair,2015-12-23 07:01:00-05:00,MDWD,neutral
817361.0,MediWound Appoints Dr. Roland Frosing as European Medical Director,2015-11-05 08:41:00-05:00,MDWD,neutral
817362.0,MediWounds Reports Q3 Loss $0.17 Vs Est Loss $0.31,2015-10-27 16:52:00-04:00,MDWD,negative
817363.0,Morning Market Gainers,2015-09-30 09:41:00-04:00,MDWD,neutral
817364.0,MediWound Awarded BARDA Contract Valued Up to $112M for Development and Procurement of NexoBrid for the U.S.,2015-09-30 07:02:00-04:00,MDWD,positive
817365.0,MediWound Finishes Enrollment in Second Phase 2 Clinical Trial of EscharEx to Treat Chronic and Other Hard-to-Heal Wounds,2015-09-01 07:31:00-04:00,MDWD,positive
817366.0,Mediwound Reports Q2 Loss of $0.19/Share vs Loss of $0.26/Share Est.,2015-08-03 16:40:00-04:00,MDWD,negative
817367.0,"Tuesday's After-Hours Movers: Ambarella, Violin Memory And More",2015-06-02 17:19:00-04:00,MDWD,neutral
817368.0,"MediWound Reports Q1 EPS $(0.30 )vs. Est. $(0.25), Rev. $67K vs. Est. $180K",2015-05-04 07:03:00-04:00,MDWD,neutral
817369.0,MediWound Initiates U.S. Phase 3 Trial With NexoBrid(R) to Treat Severe Burns,2015-04-20 08:07:00-04:00,MDWD,neutral
817370.0,MediWound Begins U.S. Phase 3 Trial With NexoBrid For Severe Burn Treatment,2015-04-20 08:03:00-04:00,MDWD,negative
817371.0,"Stocks With Unusual Volume For Jan 27: HQY, PCCC, NVMI, MDWD, PVCT",2015-01-27 15:00:00-05:00,MDWD,neutral
817372.0,MediWound Expands Distribution of NexoBrid to Mexico Through Agreement with COVALEO SA,2015-01-20 08:03:00-05:00,MDWD,positive
817373.0,MediWound Initiates Post-Marketing Study with NexoBrid To Treat Severe Burns in Pediatric Patients ,2014-11-03 07:34:00-05:00,MDWD,neutral
817374.0,Mediwound Reports Q2 EPS of $(0.28); Revenue of $39.0K,2014-07-31 06:53:00-04:00,MDWD,neutral
817375.0,MediWound Signs Deal to Have Product Marketed in Korea,2014-05-30 07:02:00-04:00,MDWD,neutral
817376.0,MediWound Starts Second Phase 2 EscharEx Trial,2014-05-21 07:06:00-04:00,MDWD,neutral
817377.0,"MediWound Announces Nirit Freikorn CMO, Carsten Henke CCO Europe, and Ety Klnger Chief R&D Officer",2014-05-12 08:18:00-04:00,MDWD,neutral
817378.0,Mediwound Reports Q1 EPS of $(0.05); Revenue of $50.0K,2014-05-02 06:06:00-04:00,MDWD,neutral
817379.0,"Oppenheimer Initiates Coverage on Mediwound Ltd. at Outperform, Announces $25.00 PT",2014-04-16 08:23:00-04:00,MDWD,neutral
817380.0,UPDATE: Credit Suisse Initiates Coverage on Mediwound Ltd. for Filling Unmet Need in Burns,2014-04-14 10:39:00-04:00,MDWD,positive
817381.0,"BMO Capital Initiates Coverage on Mediwound Ltd. at Outperform, Announces $20.00 PT",2014-04-14 08:20:00-04:00,MDWD,neutral
817382.0,"Jefferies Initiates Coverage on Mediwound Ltd. at Buy, Announces $19.00 PT",2014-04-14 08:20:00-04:00,MDWD,neutral
817383.0,"Credit Suisse Initiates Coverage on Mediwound Ltd. at Outperform, Announces $18.00 PT",2014-04-14 06:56:00-04:00,MDWD,positive
817384.0,Shares of MediWound Gained 23% in First Day of Trading,2014-03-21 11:57:00-04:00,MDWD,positive
817385.0,"MediWound Shares Open for Trade at $16/Share, Priced at $14",2014-03-20 10:26:00-04:00,MDWD,positive
817386.0,"Waiting on IPOs for MediWound, Akebia Therapeutics: MDWD to Open for Quote at 10:10AM EDT, Open for Trade at 10:25AM, AKBA to Open for Quote at 10:35AM, to Open for Trade at 10:50AM",2014-03-20 09:38:00-04:00,MDWD,neutral
817387.0,MediWound 5M-Share IPO Expected Price Range $14-$16/Share,2014-03-03 17:12:00-05:00,MDWD,neutral
817388.0,"UPDATE: Mediwound IPO Registration for $86.25M, Will List on NASDAQ Under 'MDWD'",2014-02-10 15:06:00-05:00,MDWD,neutral
817389.0,MediWound Files for IPO,2014-02-10 14:58:00-05:00,MDWD,neutral
